GSK to support manufacture of Novavax Covid-19 jab at Barnard Castle facility

A deal has been agreed to support the manufacturing of up to 60 million doses of the Novavax coronavirus vaccine within the UK.

Pharmaceutical large GlaxoSmithKline (GSK) will present “fill and end” manufacturing capability at its Barnard Castle facility within the North East starting as early as May.

Boris Johnson stated the deal between GSK, Novavax and the UK Government vaccines taskforce will “additional increase our vaccine rollout”.

The “fill and end” is the completion stage of vaccine manufacturing, making ready vials of the ultimate vaccine and packaging them for distribution and use.

The GSK web site at Barnard Castle is a specialised facility in GSK’s international manufacturing community which helps manufacturing of GSK pharmaceutical and vaccine merchandise.

The UK Government has secured 60 million doses of the vaccine underneath an advance buy settlement with Novavax.

The protein antigen element of NVX-CoV2373 can be produced within the North East of England by Novavax’s manufacturing associate, FUJIFILM Diosynth Biotechnologies, at their web site in Billingham, Stockton-on-Tees.

Mr Johnson stated: “I’m delighted by GSK’s funding, which reveals the power of UK manufacturing, and can additional increase our vaccine rollout.

“The vaccines taskforce has labored hand in glove with enterprise to efficiently ship vaccines to the entire of the UK and this settlement will proceed to support our strategy.

“We stay on observe to provide a primary jab to all over-50s by April 15, and all adults by the top of July, and I would like to as soon as once more encourage everybody to come ahead for a vaccine once you’re referred to as.”

Roger Connor, president of GSK vaccines, stated: “GSK is delighted to support Novavax and the UK vaccines taskforce with this manufacturing association for the UK and our Barnard Castle facility is now endeavor the speedy preparation work required to manufacture up to 60 million doses of this vaccine.

“We have ensured that we are able to ship these volumes with out impacting provide of our different very important medicines and vaccines, and with out disruption to the opposite Covid-19 collaborations GSK is engaged in globally.”

Earlier this month, the corporate behind the Novavax jab introduced it’s 86% efficient towards the Kent variant and 96% efficient in stopping instances attributable to the unique pressure of the coronavirus.

According to outcomes of section three trial within the UK, the jab presents 100% safety towards extreme illness, together with all hospital admission and demise.



Please enter your comment!
Please enter your name here